
Syn2bio S.A.
Research and experimental development in natural sciences and engineering
Overview
Syn2bio is a company focused on research and development of innovative pharmaceuticals, specifically working on a cardiomarker project and new pharmaceutical molecules. It conducts preclinical and clinical studies, registration, and commercialization of these medical products, including a novel radiopharmaceutical for diagnosing heart diseases.
Financials
Filing timeliness
The financial statement for 2025 was filed on time and audited by a statutory auditor.
- 202501/12/2025
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Stock quotes
- Open
- PLN 62.60
- High
- PLN 62.60
- Low
- PLN 58.60
- Volume
- 21.75K
- Avg. vol.
- 14.82K
- Market cap
- PLN 518.34M
- P/E ratio
- –
- EPS
- -PLN 1.08
- Shares outstanding
- 8.73M
- 52-week
- PLN 57.10 – 65.78
- Dividend yield
- –
- Dividend
- –
- Ex dividend date
- –
- ISIN
- PLSNBIO00013
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | – | USD -3.07m | USD -2.54m |
| Q1 2026 | – | – | – |
| Q3 2025 | – | – | – |
Results:Dec 3, 2026
News

Syn2bio shares join the sWIG80 index

Syn2bio summarizes its third fiscal quarter: SYN2 cardiac marker studies in Europe on schedule, preparations for US studies

Syn2bio publishes its first periodic report

Syn2bio among the best GPW companies in May according to Parkiet

Extraordinary general meeting of shareholders will take place on May 19

Syn2bio makes its stock market debut on the WSE
Industry
Offer
- Research and development of radiopharmaceuticals
- Radiopharmaceutical for diagnosing heart diseases
- Cardiac tracer
Websites
The site is available in: Polish and English.
- syn2bio.plSyn2bio – Innowacyjne projekty B+R dla radiofarmacjiWordPressGoogle Tag ManagerPPolylangApache
Trademarks
The company currently holds no active trademarks with the Polish Patent Office. 1 application is pending. The first mark was filed in 2025.
| Mark | Protected until | |
|---|---|---|
| syn²bio (word) | – |
Authorized Representatives
Manner of representation
If the management board is a multi-member management board, the President of the Management Board independently, or two members of the management board acting jointly, or one member of the management board jointly with a commercial proxy, are authorized to submit declarations of will on behalf of the company.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2025-10-15.
12 1090 1056 0000 0001 6263 8080
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Jun 30, 2026 | Call to creditors |
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Roche Polska sp. z o.o. | $799,694,562.77 | roche.pl | ||
| Aslab Science P.S.A. | $1,504,132.17 | aslabsci.com | ||
| Nanogroup S.A. | $843,099.47 | nanogroup.eu | ||
| Bioresearch Group sp. z o.o. | $776,186.19 | bioresearch.pl | ||
| CTI Clinical Trial and Consulting Services Poland sp. z o.o. | $527,145.56 | ctifacts.com | ||
| Medicofarma Biotech S.A. | $314,882.33 | medicofarmabiotech.pl | ||
| Genelytica sp. z o.o. | $213,207.91 | genelytica.pl | ||
| Orphinic Scientific S.A. | $42,972.42 | orphinic.com | ||
| Purevidence sp. z o.o. | $4,997.49 | purevidence.pl | ||
| Nanothea S.A. | $115.78 | nanothea.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-03-27 | Share capital increase (100,000.00 PLN → 4,364,564.50 PLN) | |
| 2025-08-07 | Entered in the register |
FAQ
Last updated: 2026-04-04